HSBC Holdings’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,409
Closed -$437K 2741
2025
Q2
$437K Sell
3,409
-7,102
-68% -$738K ﹤0.01% 2218
2025
Q1
$914K Sell
10,511
-9,508
-47% -$928K ﹤0.01% 1792
2024
Q4
$1.73M Sell
20,019
-11,795
-37% -$1.08M ﹤0.01% 1533
2024
Q3
$2.9M Buy
31,814
+21,850
+219% +$2.17M ﹤0.01% 1306
2024
Q2
$1.06M Buy
+9,964
New +$997K ﹤0.01% 1660
2023
Q4
Sell
-5,856
Closed -$298K 2733
2023
Q3
$298K Sell
5,856
-346
-6% -$18.5K ﹤0.01% 2224
2023
Q2
$404K Sell
6,202
-9,138
-60% -$497K ﹤0.01% 2042
2023
Q1
$689K Sell
15,340
-8,019
-34% -$361K ﹤0.01% 1922
2022
Q4
$1M Buy
23,359
+4,269
+22% +$205K ﹤0.01% 1967
2022
Q3
$1.28M Sell
19,090
-19,463
-50% -$1.25M ﹤0.01% 1723
2022
Q2
$1.99M Buy
38,553
+12,872
+50% +$754K ﹤0.01% 1587
2022
Q1
$1.66M Buy
+25,681
New +$1.84M ﹤0.01% 1692
2021
Q4
Sell
-3,701
Closed -$382K 3259
2021
Q3
$382K Sell
3,701
-2,478
-40% -$231K ﹤0.01% 2417
2021
Q2
$544K Buy
6,179
+1,807
+41% +$166K ﹤0.01% 2116
2021
Q1
$422K Sell
4,372
-3,248
-43% -$324K ﹤0.01% 2088
2020
Q4
$854K Buy
+7,620
New +$803K ﹤0.01% 1805
2019
Q3
Sell
-2,521
Closed -$238K 3066
2019
Q2
$238K Sell
2,521
-254
-9% -$21K ﹤0.01% 2451
2019
Q1
$222K Buy
+2,775
New +$205K ﹤0.01% 2497

Other funds holding BPMC

HSBC Holdings's BPMC Position: Q3 2025 in Review

HSBC Holdings sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3,409 shares — an estimated $437K sold.

HSBC Holdings first reported a position in BPMC in Q1 2019 and held it in 18 quarters. The position peaked at $2.9M in Q3 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • HSBC Holdings reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 3,409 Blueprint Medicines shares in Q3 2025, an estimated $437K.
  • HSBC Holdings first reported a position in Blueprint Medicines in Q1 2019 and held it in 18 quarters.
  • HSBC Holdings's Blueprint Medicines position peaked at $2.9M in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.